FIBIN: A Protein Involved in Blood Clots and Potential Drug Targets

Target Name: FIBIN

NCBI ID: G387758

FIBIN

Other Name(s): fin bud initiation factor homolog | FIBIN_HUMAN | Fin bud initiation factor homolog

FIBIN: A Protein Involved in Blood Clots and Potential Drug Targets

Fibin is a protein that is expressed in various tissues throughout the body, including the liver, heart, and kidneys. It is a key component of blood clots, which are blood-based structures that can cause blockages in the blood vessels. Fibin is involved in the formation of these blood clots and has been identified as a potential drug target or biomarker for various diseases.

The FIBIN gene was identified in the late 1990s as a key regulator of blood clot formation. The gene encodes a protein that is composed of several hundred amino acids. Fibin functions as a scaffold protein that helps to organize the clotting factors that are required for blood clot formation. These factors include the protein thrombin, which is a key clotting enzyme, as well as several factors that help to regulate the stickiness of the clotting factors to the damaged blood vessel surface.

FIBIN has been shown to play a crucial role in the formation of both micro- and macro- blood clots. Micro-clots, also known as arterial thrombots, are small clots that form in the smallest blood vessels, such as those in the lungs, heart, and kidneys. Macro-clots, on the other hand, are larger clots that form in larger blood vessels, such as those in the legs, arms, and brain.

FIBIN has been shown to be involved in the formation of both types of clots. For example, studies have shown that Fibin is involved in the formation of micro-clots in the lungs, heart, and kidneys. Additionally, research has suggested that Fibin may be involved in the formation of macro-clots in the legs, arms, and brain.

FIBIN has also been shown to be involved in the regulation of the stickiness of the clotting factors to the damaged blood vessel surface. This is important because the stickiness of the clotting factors is critical for the formation of stable blood clots. By regulating the stickiness of the clotting factors, Fibin helps to ensure that the clots are able to stick together long enough to form.

FIBIN has also been shown to be involved in the regulation of the growth and differentiation of blood cells. For example, studies have shown that Fibin plays a role in the production of new red blood cells in the bone marrow. Additionally, Fibin has been shown to be involved in the regulation of the production of platelets in the liver.

In addition to its role in blood clot formation, Fibin has also been shown to have potential as a drug target or biomarker for various diseases. For example, research has suggested that Fibin may be involved in the development of thromboembolic diseases, such as heart attack and stroke. Additionally, Fibin has been shown to be involved in the development of cancer, and may be a useful biomarker for monitoring the effectiveness of cancer treatments.

Overall, FIBIN is a protein that has been shown to be involved in various aspects of blood clot formation and has potential as a drug target or biomarker for various diseases. Further research is needed to fully understand the role of FIBIN in these processes and to determine its potential as a therapeutic agent.

Protein Name: Fin Bud Initiation Factor Homolog

The "FIBIN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FIBIN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets